JP2018537536A - Ｈｅｒ２陽性転移性乳癌の治療のための組成物および方法 - Google Patents

Ｈｅｒ２陽性転移性乳癌の治療のための組成物および方法 Download PDF

Info

Publication number
JP2018537536A
JP2018537536A JP2018549407A JP2018549407A JP2018537536A JP 2018537536 A JP2018537536 A JP 2018537536A JP 2018549407 A JP2018549407 A JP 2018549407A JP 2018549407 A JP2018549407 A JP 2018549407A JP 2018537536 A JP2018537536 A JP 2018537536A
Authority
JP
Japan
Prior art keywords
cancer
cells
activated
receptor
kit according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018549407A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537536A5 (enExample
Inventor
ラビザド，シャールーズ
スン−シオン，パトリック
クリングマン，ハンス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nant Holdings IP LLC
Original Assignee
Nant Holdings IP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nant Holdings IP LLC filed Critical Nant Holdings IP LLC
Publication of JP2018537536A publication Critical patent/JP2018537536A/ja
Publication of JP2018537536A5 publication Critical patent/JP2018537536A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018549407A 2015-12-09 2016-12-09 Ｈｅｒ２陽性転移性乳癌の治療のための組成物および方法 Pending JP2018537536A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562265382P 2015-12-09 2015-12-09
US62/265,382 2015-12-09
PCT/US2016/066018 WO2017100709A1 (en) 2015-12-09 2016-12-09 Compositions and methods for treatment of her2 positive metastatic breast cancer

Publications (2)

Publication Number Publication Date
JP2018537536A true JP2018537536A (ja) 2018-12-20
JP2018537536A5 JP2018537536A5 (enExample) 2019-12-12

Family

ID=59013368

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018549407A Pending JP2018537536A (ja) 2015-12-09 2016-12-09 Ｈｅｒ２陽性転移性乳癌の治療のための組成物および方法

Country Status (8)

Country Link
US (1) US20180360881A1 (enExample)
EP (1) EP3386522A4 (enExample)
JP (1) JP2018537536A (enExample)
KR (1) KR20180123214A (enExample)
CN (1) CN109475576A (enExample)
AU (1) AU2016366677A1 (enExample)
CA (1) CA3007996A1 (enExample)
WO (1) WO2017100709A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018013975A1 (en) * 2016-07-15 2018-01-18 Viracta Therapeutics, Inc. Hdac inhibitors for use with nk cell based therapies
AU2018289572A1 (en) * 2017-06-22 2020-01-23 University Of Southern California Combination cancer therapy using chimeric antigen receptor engineered natural killer cells as chemotherapeutic drug carriers
KR20230115351A (ko) * 2017-08-15 2023-08-02 난트셀, 인크. Hank 세툭시맙 조합 및 방법
CN110484507B (zh) * 2018-01-31 2023-10-13 温州医科大学 一种靶向肿瘤Her2的新型嵌合抗原受体T细胞的制备技术
IL321548A (en) * 2018-05-22 2025-08-01 Immunitybio Inc Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
EP3834843A4 (en) * 2018-08-06 2022-05-11 Daiichi Sankyo Company, Limited COMBINATION OF ANTIBODY-DRUG CONJUGATE AND TUBULIN INHIBITOR
WO2020091868A1 (en) 2018-10-31 2020-05-07 Nantkwest, Inc. Elimination of pd-l1-positive malignancies by pd-l1 chimeric antigen receptor-expressing nk cells
EP4003376A4 (en) * 2019-07-26 2023-09-06 Nantkwest, Inc. CD16+NK-92 CELLS PRELOADED WITH ANTIBODIES AS AN EFFECTIVE THERAPEUTIC PRODUCT FOR TUMOR LYSIS
KR102594083B1 (ko) 2020-07-07 2023-10-25 칸큐어 엘엘씨 Mic 항체 및 결합제 및 이의 사용 방법
CN112675313A (zh) * 2020-12-28 2021-04-20 烟台大学 连接曲妥珠单抗片段的美登素纳米粒组合物
CN114807237A (zh) * 2022-05-12 2022-07-29 广东普罗凯融生物医药科技有限公司 一种过表达CD16a的NK细胞的制备方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009169A1 (en) * 2002-02-25 2004-01-15 Julie Taylor Administration of agents for the treatment of inflammation
JP2012193180A (ja) * 2005-04-15 2012-10-11 Macrogenics Inc 共有結合型ダイアボディとその使用
JP2018509459A (ja) * 2015-03-27 2018-04-05 ナントクエスト インコーポレイテッド がん治療薬との併用療法におけるｎｋ−９２細胞

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE531733T1 (de) * 2005-01-06 2011-11-15 Novo Nordisk As Kir-bindende wirkstoffe und verfahren zu ihrer verwendung
EP2161339A1 (en) * 2008-08-29 2010-03-10 F. Hoffmann-La Roche Ag ADCC with modified NK92 cells
KR102476640B1 (ko) * 2013-11-01 2022-12-09 이뮤너티바이오, 인크. 종양세포 치사활성 및 항균성 조성물 및 방법
AU2015235852B2 (en) * 2014-03-28 2019-08-15 Regents Of The University Of Minnesota Polypeptides, cells, and methods involving engineered CD16

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009169A1 (en) * 2002-02-25 2004-01-15 Julie Taylor Administration of agents for the treatment of inflammation
JP2005526045A (ja) * 2002-02-25 2005-09-02 エラン ファーマシューティカルズ，インコーポレイテッド 炎症の治療用薬剤の投与
JP2012193180A (ja) * 2005-04-15 2012-10-11 Macrogenics Inc 共有結合型ダイアボディとその使用
JP2018509459A (ja) * 2015-03-27 2018-04-05 ナントクエスト インコーポレイテッド がん治療薬との併用療法におけるｎｋ−９２細胞

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, vol. 76(4)Supplement, JPN6021026601, February 2016 (2016-02-01), pages 2 - 11, ISSN: 0004545629 *
EJC SUPPLEMENTS, vol. 8(1), JPN6020046433, 2010, pages 1 - 10, ISSN: 0004639692 *
J. IMMUNOL., vol. 180, JPN6020046432, 2008, pages 6392 - 6401, ISSN: 0004639691 *
ONCOTARGET, vol. 7(52), JPN6020046430, November 2016 (2016-11-01), pages 86359 - 86373, ISSN: 0004639689 *
THE AMERICAN SOCIETY OF GENE & CELL THERAPY, vol. 23(2), JPN6020046431, February 2015 (2015-02-01), pages 330 - 338, ISSN: 0004639690 *
医薬品添付文書 抗悪性腫瘍剤 パクリタキセル, JPN6021026600, September 2015 (2015-09-01), ISSN: 0004545628 *

Also Published As

Publication number Publication date
CA3007996A1 (en) 2017-06-15
AU2016366677A1 (en) 2018-07-26
CN109475576A (zh) 2019-03-15
EP3386522A4 (en) 2019-06-19
WO2017100709A1 (en) 2017-06-15
KR20180123214A (ko) 2018-11-15
US20180360881A1 (en) 2018-12-20
EP3386522A1 (en) 2018-10-17

Similar Documents

Publication Publication Date Title
JP2018537536A (ja) Ｈｅｒ２陽性転移性乳癌の治療のための組成物および方法
García-Foncillas et al. Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors
JP6748221B2 (ja) 細胞免疫療法前の細胞毒性プレコンディショニングの代替
KR100386492B1 (ko) 괴사유발물질과괴사에의해활성화되는물질을함유하는,종양및염증질환치료용배합제제로서의약제학적조성물
JP7770929B2 (ja) Ｃａｒ－ｔ細胞のインサイチュ動員、リプログラミングおよび放出
ES2924138T3 (es) Nueva composición farmacéutica que comprende partículas que comprenden un complejo de un polirribonucleótido de doble cadena y una polialquilenimina
CN108472317A (zh) 修饰免疫细胞及其用途
Aghajani et al. Current approaches in glioblastoma multiforme immunotherapy
Kim et al. Current trends and innovative approaches in cancer immunotherapy
JP2022017358A (ja) 癌の治療のための抗ｆｕｇｅｔａｃｔｉｃ剤の局所的送達
Gatto et al. Glioblastoma treatment slowly moves toward change: novel druggable targets and translational horizons in 2022
CA3073744A1 (en) Aldoxorubicin combination treatments and methods
JP7062754B2 (ja) ｈａＮＫセツキシマブ併用及び方法
JP2018531229A6 (ja) 癌の治療のための抗ｆｕｇｅｔａｃｔｉｃ剤の局所的送達
US20180117006A1 (en) Anti-fugetactic agent and immunotherapy agent combination therapy and compositions for the treatment of cancer
KR20210097101A (ko) 표적화 모이어티-약물 이식된 면역 세포 조성물 및 사용 방법
JP7098518B2 (ja) 抗ｆｕｇｅｔａｃｔｉｃ特性を有する改変されたナチュラルキラー細胞およびその使用
Jensen et al. CarboCell combinatorial immunotherapy orchestrates curative anticancer immune activation of the tumor microenvironment
Wang et al. Targets Selection for Precision Therapy of Relapsed/Refractory Multiple Myeloma: the Latest Advancements
Sarangi et al. Principles of Chemotherapy, Targeted Therapy, and Immunotherapy in Gynaecological Malignancies
Zitvogel et al. Trial watch
EA043393B1 (ru) Замена цитотоксического предварительного кондиционирования перед клеточной иммунотерапией
JP2018527010A (ja) 抗ｆｕｇｅｔａｃｔｉｃ特性を有する改変されたＴ細胞およびその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201208

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210224

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211005

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211116